Animal studies have suggested a synergistic analgesic effect when cannabinoids are combined with opioids. The results from one pharmacokinetic interaction study have been reported. In this study, 21 patients with chronic pain were administered vaporized Cannabis along with sustained-release morphine or oxycodone for 5 days. The patients who received vaporized Cannabis and sustained-release morphine had a statistically significant decrease in their mean pain score over the 5-day period; those who received vaporized Cannabis and oxycodone did not. These findings should be verified by further studies before recommendations favoring such an approach are warranted in general clinical practice.
Heavy, long term exposure to marijuana may have biologically-based physical, mental, behavioral and social health consequences and may be "associated with diseases of the liver (particularly with co-existing hepatitis C), lungs, heart, and vasculature". It is recommended that cannabis use be stopped before and during pregnancy as it can result in negative outcomes for both the mother and baby. However, maternal use of marijuana during pregnancy does not appear to be associated with low birth weight or early delivery after controlling for tobacco use and other confounding factors. A 2014 review found that while cannabis use may be less harmful than alcohol use, the recommendation to substitute it for problematic drinking is premature without further study. Other side effects include cannabinoid hyperemesis syndrome.
Traditionally, hemp stalks would be water-retted first before the fibers were beaten off the inner hurd by hand, a process known as scutching. As mechanical technology evolved, separating the fiber from the core was accomplished by crushing rollers and brush rollers that would produce a nearly clean fiber. After the Marijuana Tax Act was implemented in 1938, the technology for separating the fibers from the core remained "frozen in time".
For centuries, industrial hemp (plant species Cannabis sativa) has been a source of fiber and oilseed used worldwide to produce a variety of industrial and consumer products. Currently, more than 30 nations grow industrial hemp as an agricultural commodity, which is sold on the world market. In the United States, however, production is strictly controlled under existing drug enforcement laws. Currently there is no large-scale commercial production in the United States and the U.S. market depends on imports.
Preclinical research suggests that emetic circuitry is tonically controlled by endocannabinoids. The antiemetic action of cannabinoids is believed to be mediated via interaction with the 5-hydroxytryptamine 3 (5-HT3) receptor. CB1 receptors and 5-HT3 receptors are colocalized on gamma-aminobutyric acid (GABA)-ergic neurons, where they have opposite effects on GABA release. There also may be direct inhibition of 5-HT3 gated ion currents through non–CB1 receptor pathways. CB1 receptor antagonists have been shown to elicit emesis in the least shrew that is reversed by cannabinoid agonists. The involvement of CB1 receptor in emesis prevention has been shown by the ability of CB1 antagonists to reverse the effects of THC and other synthetic cannabinoid CB1 agonists in suppressing vomiting caused by cisplatin in the house musk shrew and lithium chloride in the least shrew. In the latter model, CBD was also shown to be efficacious.[37,38]
Medical marijuana in the U.S. is controlled at the state level. Per federal law, cannabis is illegal as noted in the Controlled Substances Act, but the federal government has stated they will not actively prosecute patients and caregivers complying with state medical marijuana laws. However, use of medical marijuana outside of the state laws for illegal use or trafficking will not be tolerated by state or federal government.
The 2014 US Farm Bill allows states that have passed their own industrial hemp legislation to grow industrial hemp for purposes of research and development. Several states — including Kentucky, Colorado, and Oregon — are already conducting hemp pilot projects. Many other states are currently pursuing similar legislation and programs. After many years of prohibition, American farmers are finally reacquainting themselves with industrial hemp.
Over the past two years, 17 states have passed laws legalizing CBD so that patients can obtain the drug without fear of prosecution from local authorities. For intractable childhood epilepsies—the sorts of seizure disorders that for centuries have ruined lives and shattered families, the ones even specialists like Hernandez dread—CBD could be a miracle cure.
The high absorbency of hemp hurds has led to their occasional use as an absorbent for oil and waste spill cleanup. Hemp as an industrial absorbent has generated some interest in Alberta, for use in land reclamation in the oil and gas industry. Because hemp hurds are a costly product, it is likely that animal bedding will remain the most important application.
Elias Anderson, one of the owners of Going Green, said representatives from HempMedsPx approached him after Krenzler published the lab’s findings on his blog. “They were like, ‘What are we gonna do about it?’” Anderson recalled, “And I was like, ‘Nothing. We have standards, and I stand behind my test results.’” Still, the company’s representatives were insistent and advised Anderson to have Kenzler take down the lab’s findings. In an email to the New Republic, Hard, the Medical Marijuana, Inc. spokesman, contended that the sample of hemp oil that Going Green Labs tested had been “tampered with” by a competitor after Krenzler obtained it. “HempMedsPX, if anything, told the lab they cannot publish results from products [for which] they had no chain of custody tracked,” Hard said, “and if they did—that could prove to be very bad for the lab.” He also characterized Krenzler and Anderson as “haters” of Medical Marijuana, Inc., and suggested that much of the criticism of the company and its products comes from commercial competitors.
California Food and Agricultural Code (FAC) Section 81001 establishes an Industrial Hemp Advisory Board to advise CDFA and make recommendations pertaining to the cultivation of industrial hemp, including industrial hemp seed law and regulations, annual budgets, and the setting of an assessment rate. FAC Section 81001 also outlines the membership and administration of the Board.
In recent decades, the neurobiology of cannabinoids has been analyzed.[12-15] The first cannabinoid receptor, CB1, was identified in the brain in 1988. A second cannabinoid receptor, CB2, was identified in 1993. The highest expression of CB2 receptors is located on B lymphocytes and natural killer cells, suggesting a possible role in immunity. Endogenous cannabinoids (endocannabinoids) have been identified and appear to have a role in pain modulation, control of movement, feeding behavior, mood, bone growth, inflammation, neuroprotection, and memory.